

Matthew D Galsky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1271591/publications.pdf>

Version: 2024-02-01

272
papers

19,575
citations

28190

55
h-index

12910

131
g-index

282
all docs

282
docs citations

282
times ranked

21465
citing authors

#	ARTICLE	IF	CITATIONS
1	TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 403-406.	0.8	9
2	Editorial for "Preliminary Exploration of the Application of Vesical Imaging Reporting and Data System (VI-RADS) in Post-Treatment Patients with Bladder Cancer: A Prospective Single-Center Study". <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 287-288.	1.9	1
3	The obesity paradox in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 472-478.	2.0	15
4	Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 35-42.	0.9	5
5	Abstract P046: NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer. , 2022, , .		0
6	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. <i>JAMA Network Open</i> , 2022, 5, e2142046.	2.8	9
7	Usability Inspection of a Mobile Cancer Telerehabilitation System. <i>Studies in Health Technology and Informatics</i> , 2022, 289, 405-409.	0.2	2
8	Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma. <i>Oncologist</i> , 2022, 27, 432-e452.	1.9	2
9	Health-related Quality of Life of Patients with Locally Advanced or Metastatic Urothelial Cancer Treated with Enfortumab Vedotin after Platinum and PD-1/PD-L1 Inhibitor Therapy: Results from Cohort 1 of the Phase 2 EV-201 Clinical Trial. <i>European Urology</i> , 2022, 81, 515-522.	0.9	14
10	Health-related Quality of Life with Adjuvant Nivolumab After Radical Resection for High-risk Muscle-invasive Urothelial Carcinoma: Results from the Phase 3 CheckMate 274 Trial. <i>European Urology Oncology</i> , 2022, 5, 553-563.	2.6	7
11	Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors. <i>Nature Communications</i> , 2022, 13, 1487.	5.8	17
12	Metastasis Within Three Years from Radical Nephroureterectomy as a Potential Surrogate for Overall Survival. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 389.e1-389.e7.	0.9	1
13	Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery. <i>Nature Medicine</i> , 2022, 28, 626-629.	15.2	12
14	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. <i>JAMA Network Open</i> , 2022, 5, e224304.	2.8	43
15	Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2837-2848.	2.0	5
16	Adjuvant immunotherapy in patients with high-risk muscle-invasive urothelial carcinoma: The potential impact of informative censoring. <i>Cancer</i> , 2022, 128, 2892-2897.	2.0	6
17	Estimating the rate and reasons of clinical trial failure in urologic oncology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 154-160.	0.8	10
18	Novel Therapies. , 2021, , 315-322.		0

#	ARTICLE	IF	CITATIONS
19	Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma. <i>Journal of Urology</i> , 2021, 205, 414-419.	0.2	3
20	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021, 128, 196-205.	1.3	18
21	Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 743-749.	2.0	4
22	Characterization of hyperglycemia in patients receiving immune checkpoint inhibitors: Beyond autoimmune insulin-dependent diabetes. <i>Diabetes Research and Clinical Practice</i> , 2021, 172, 108633.	1.1	10
23	The impact of the globalization of cancer clinical trials on the enrollment of Black patients. <i>Cancer</i> , 2021, 127, 2294-2301.	2.0	11
24	Abstract S06-02: Disruption to care of patients with thoracic malignancies: A COVID-19 and cancer outcomes study. , 2021, , .		0
25	Myeloid Cell-associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing. <i>Clinical Cancer Research</i> , 2021, 27, 4287-4300.	3.2	42
26	Characterizing Prostate-Specific Antigen Levels at Death in Patients with Metastatic Castration-Resistant Prostate Cancer: Are We Underutilizing Imaging?. <i>Clinical Genitourinary Cancer</i> , 2021, , .	0.9	0
27	An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. <i>Nature Medicine</i> , 2021, 27, 793-801.	15.2	56
28	Real World Outcomes of Patients with Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 597-612.	0.9	6
29	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 464-472.	2.6	39
30	The effect of adding immune checkpoint inhibitors on the risk of pneumonitis for solid tumours: a meta-analysis of phase III randomised controlled trials. <i>European Journal of Cancer</i> , 2021, 150, 168-178.	1.3	11
31	Metabolic disease and adverse events from immune checkpoint inhibitors. <i>European Journal of Endocrinology</i> , 2021, 184, 857-865.	1.9	12
32	Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 2102-2114.	13.9	427
33	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. , 2021, 9, e002552.		16
34	Abstract 2188: Urothelial cancer-GENOMIC analysis to improve patient outcomes and research (UC-GENOME): a bladder cancer advocacy network (BCAN) led collaborative research study. , 2021, , .		0
35	Efficacy of Platinum Rechallenge in Metastatic Urothelial Carcinoma After Previous Platinum-Based Chemotherapy for Metastatic Disease. <i>Oncologist</i> , 2021, 26, 1026-1034.	1.9	8
36	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. <i>JAMA Oncology</i> , 2021, 7, 1167.	3.4	149

#	ARTICLE	IF	CITATIONS
37	Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. <i>Future Oncology</i> , 2021, 17, 3137-3150.	1.1	21
38	Pan-cancer proteogenomic investigations identify post-transcriptional kinase targets. <i>Communications Biology</i> , 2021, 4, 1112.	2.0	5
39	Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop. <i>Nature Reviews Urology</i> , 2021, , .	1.9	6
40	The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic. <i>Frontiers in Oncology</i> , 2021, 11, 734963.	1.3	4
41	Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study. <i>Lung Cancer</i> , 2021, 160, 78-83.	0.9	10
42	621â€¦NKG2A and HLA-E define a novel mechanism of resistance to immunotherapy with M. bovis BCG in non-muscle-invasive bladder cancer patients. , 2021, 9, A651-A651.		0
43	314â€¦NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer. , 2021, 9, A338-A338.		1
44	82â€¦Single-cell RNA sequencing and CITE-Seq analysis of bladder cancer patient urine with matched tumor and peripheral blood suggests urine as a window into the tumor immune microenvironment. , 2021, 9, A90-A90.		0
45	Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers. <i>European Urology Oncology</i> , 2020, 3, 671-679.	2.6	11
46	Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database. <i>European Urology Oncology</i> , 2020, 3, 94-101.	2.6	41
47	What Is the Significance of Variant Histology in Urothelial Carcinoma?. <i>European Urology Focus</i> , 2020, 6, 653-663.	1.6	126
48	Comparative Effectiveness of Robotic-Assisted Surgery for Resectable Lung Cancer in Older Patients. <i>Chest</i> , 2020, 157, 1313-1321.	0.4	44
49	The natural history of untreated muscleâ€“invasive bladder cancer. <i>BJU International</i> , 2020, 125, 270-275.	1.3	72
50	First-line immune checkpoint inhibitor use in cisplatin-eligible patients with advanced urothelial carcinoma: a secular trend analysis. <i>Future Oncology</i> , 2020, 16, 4341-4345.	1.1	10
51	Protein phosphatase 2A activation as a therapeutic strategy for managing MYC-driven cancers. <i>Journal of Biological Chemistry</i> , 2020, 295, 757-770.	1.6	24
52	Impact of performance status on treatment outcomes: A realâ€“world study of advanced urothelial cancer treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 1208-1216.	2.0	70
53	Durable disease control with local treatment for oligoprogression of metastatic solid tumors treated with immune checkpoint blockade. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100216.	0.7	6
54	Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1â€“3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3â€“altered Advanced/Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2020, 78, 916-924.	0.9	18

#	ARTICLE	IF	CITATIONS
55	Impact of timing of adjuvant chemotherapy following radical cystectomy for bladder cancer on patient survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 934.e1-934.e9.	0.8	2
56	Assessing Genitourinary Cancer Clinical Trial Accrual Sufficiency Using Archived Trial Data. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 614-622.	1.0	12
57	Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. <i>European Urology Oncology</i> , 2020, 3, 728-738.	2.6	61
58	Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study. <i>Cancer Cell</i> , 2020, 38, 769-770.	7.7	54
59	Treatment of muscle-invasive and advanced bladder cancer in 2020. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 404-423.	157.7	507
60	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. <i>Cancer Discovery</i> , 2020, 10, 1514-1527.	7.7	108
61	Survival of Patients with Muscle-Invasive Urothelial Cancer of the Bladder with Residual Disease at Time of Cystectomy: A Comparative Survival Analysis of Treatment Modalities in the National Cancer Database. <i>Bladder Cancer</i> , 2020, 6, 265-276.	0.2	5
62	Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer. <i>Journal of Immunotherapy</i> , 2020, 43, 291-298.	1.2	7
63	Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1574-1588.	5.1	324
64	Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. <i>Cancer Cell</i> , 2020, 38, 489-499.e3.	7.7	216
65	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <i>Cancer Cell</i> , 2020, 38, 761-766.	7.7	26
66	Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 638-645.	2.0	9
67	Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2020, 395, 1547-1557.	6.3	546
68	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet</i> , The, 2020, 395, 1907-1918.	6.3	1,395
69	Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275. <i>Clinical Cancer Research</i> , 2020, 26, 5120-5128.	3.2	79
70	<i>ARID1A</i> mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	82
71	Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. <i>Cancer</i> , 2020, 126, 2597-2606.	2.0	39
72	A reference profile-free deconvolution method to infer cancer cell-intrinsic subtypes and tumor-type-specific stromal profiles. <i>Genome Medicine</i> , 2020, 12, 24.	3.6	34

#	ARTICLE	IF	CITATIONS
73	Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e543-e556.	0.9	22
74	Selective PP2A Enhancement through Biased Heterotrimer Stabilization. <i>Cell</i> , 2020, 181, 688-701.e16.	13.5	107
75	Neoadjuvant versus adjuvant chemotherapy for upper tract urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 684.e9-684.e15.	0.8	8
76	Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1797-1806.	0.8	102
77	Clinical Complete Response after Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Call for Standardized Assessments and Definitions. <i>European Urology Focus</i> , 2020, 6, 627-629.	1.6	10
78	Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers. <i>Nature Communications</i> , 2020, 11, 2540.	5.8	40
79	Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 503-512.	1.1	11
80	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. <i>Journal of Urology</i> , 2020, 204, 63-70.	0.2	32
81	Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. <i>Journal of Urology</i> , 2020, 204, 1173-1179.	0.2	47
82	The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies. <i>PLoS ONE</i> , 2020, 15, e0240169.	1.1	8
83	PD-1 inhibitors for urothelial cancer: combination or sequential therapy? " Authors' reply. <i>Lancet</i> , The, 2020, 396, 1977-1978.	6.3	0
84	289...PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting. , 2020, , .		0
85	The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies. , 2020, 15, e0240169.		0
86	The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies. , 2020, 15, e0240169.		0
87	The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies. , 2020, 15, e0240169.		0
88	The SRG rat, a Sprague-Dawley Rag2/Il2rg double-knockout validated for human tumor oncology studies. , 2020, 15, e0240169.		0
89	DNA damage response as biomarkers informing a precision medicine approach to bladder cancer: what are the next steps?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 7-9.	0.4	0
90	The clinical and economic burden of perioperative complications of radical cystectomy. <i>Translational Andrology and Urology</i> , 2019, 8, S277-S279.	0.6	3

#	ARTICLE	IF	CITATIONS
91	Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. <i>European Urology</i> , 2019, 76, 425-429.	0.9	15
92	Conditionally Reprogrammed Patient-derived Cells: A Step Forward Towards Personalized Medicine?. <i>European Urology</i> , 2019, 76, 435-436.	0.9	6
93	Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer. <i>European Urology</i> , 2019, 76, 524-532.	0.9	38
94	Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 2592-2600.	0.8	404
95	Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. <i>European Urology</i> , 2019, 76, 599-603.	0.9	95
96	Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis. , 2019, 7, 248.		18
97	Association Between FDA Label Restriction and Immunotherapy and Chemotherapy Use in Bladder Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1209.	3.8	20
98	Chemotherapy regimen is associated with venous thromboembolism risk in patients with urothelial tract cancer. <i>BJU International</i> , 2019, 124, 290-296.	1.3	3
99	The impact of pathologic response to neoadjuvant chemotherapy on conditional survival among patients with muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 572.e21-572.e28.	0.8	14
100	Prostate Cancer in World Trade Center Responders Demonstrates Evidence of an Inflammatory Cascade. <i>Molecular Cancer Research</i> , 2019, 17, 1605-1612.	1.5	21
101	Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analyses. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1089-1098.	1.0	20
102	Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer. <i>Cancer</i> , 2019, 125, 3155-3163.	2.0	32
103	Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2019, 76, 782-789.	0.9	38
104	Atezolizumab in "Real World" Patients: Do Phase 3b Trials Help Bridge the Gap Between Efficacy and Effectiveness?. <i>European Urology</i> , 2019, 76, 82-83.	0.9	0
105	Pathological downstaging as a novel endpoint for the development of neoadjuvant chemotherapy for upper tract urothelial carcinoma. <i>BJU International</i> , 2019, 124, 665-671.	1.3	34
106	Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real-World Practice. <i>Oncologist</i> , 2019, 24, e397-e399.	1.9	33
107	Cisplatin Ineligibility for Patients With Metastatic Urothelial Carcinoma: A Survey of Clinical Practice Perspectives Among US Oncologists. <i>Bladder Cancer</i> , 2019, 5, 281-288.	0.2	14
108	Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. <i>European Urology Oncology</i> , 2019, 2, 248-256.	2.6	11

#	ARTICLE	IF	CITATIONS
109	<p>Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives</p>. ClinicoEconomics and Outcomes Research, 2019, Volume 11, 659-672.	0.7	2
110	The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. Oncologist, 2019, 24, 1348-1355.	1.9	10
111	Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2019, 17, 7-14.e3.	0.9	9
112	A delay of 8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 116-122.	0.8	24
113	SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. World Journal of Urology, 2019, 37, 95-105.	1.2	19
114	Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. European Urology Focus, 2019, 5, 242-249.	1.6	11
115	SAT-094 Overweight and Obesity Associated with Immune-Related Adverse Events in Patients on Immune Checkpoint Inhibitor Therapy. Journal of the Endocrine Society, 2019, 3, .	0.1	1
116	Obesity and metastatic castration resistant prostate cancer: Results from the control arms of ASCENT2, MAINSAL and VENICE trials.. Journal of Clinical Oncology, 2019, 37, 287-287.	0.8	0
117	The impact of pathologic downstaging with neoadjuvant chemotherapy on survival of patients with muscle-invasive bladder cancer.. Journal of Clinical Oncology, 2019, 37, 491-491.	0.8	0
118	SUN-417 Recovery Of Central Adrenal Insufficiency In A Patient With Hypophysitis Secondary To Immune Checkpoint Inhibitors Therapy. Journal of the Endocrine Society, 2019, 3, .	0.1	0
119	MON-603 Racial Distribution of Endocrine Complications in Oncology Patients Treated with Immune Checkpoint Inhibitors. Journal of the Endocrine Society, 2019, 3, .	0.1	0
120	Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer. Cancer Research, 2018, 78, 2065-2080.	0.4	60
121	Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. European Urology, 2018, 73, 751-759.	0.9	99
122	Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. European Urology Focus, 2018, 4, 937-945.	1.6	7
123	Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. Clinical Genitourinary Cancer, 2018, 16, e483-e490.	0.9	12
124	Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. Acta Oncologica, 2018, 57, 491-497.	0.8	22
125	Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors. Clinical Genitourinary Cancer, 2018, 16, e161-e167.	0.9	3
126	Advancing care through genomics and immune checkpoint blockade. Nature Reviews Urology, 2018, 15, 71-72.	1.9	8

#	ARTICLE	IF	CITATIONS
127	Early Mortality in Patients With Muscle-Invasive Bladder Cancer Undergoing Cystectomy in the United States. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky075.	1.4	14
128	Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database. <i>Frontiers in Oncology</i> , 2018, 8, 463.	1.3	27
129	Real World Experience of Drug Induced Liver Injury in Patients Undergoing Chemotherapy. <i>Journal of Clinical Gastroenterology and Hepatology</i> , 2018, 02, .	0.2	19
130	Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. <i>Journal of Urology</i> , 2018, 200, 1207-1214.	0.2	26
131	EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. <i>Nature Communications</i> , 2018, 9, 3503.	5.8	224
132	Current Role of Checkpoint Inhibitors in Urologic Cancers. <i>Cancer Treatment and Research</i> , 2018, 175, 241-258.	0.2	5
133	Efficacy of BCJ398, a Fibroblast Growth Factor Receptor 1 α 3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> Alterations. <i>Cancer Discovery</i> , 2018, 8, 812-821.	7.7	206
134	Identification of microR-106b as a prognostic biomarker of p53-like bladder cancers by ActMiR. <i>Oncogene</i> , 2018, 37, 5858-5872.	2.6	20
135	Premature Clinical Trial Discontinuation in the Era of Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2018, 23, 1494-1499.	1.9	15
136	Effectiveness of Transurethral Resection plus Systemic Chemotherapy as Definitive Treatment for Muscle Invasive Bladder Cancer in Population Level Data. <i>Journal of Urology</i> , 2018, 200, 996-1004.	0.2	14
137	Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States. <i>Bladder Cancer</i> , 2018, 4, 227-238.	0.2	55
138	Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import. <i>Cell</i> , 2018, 174, 1200-1215.e20.	13.5	96
139	Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer. <i>World Journal of Urology</i> , 2018, 36, 1741-1748.	1.2	13
140	Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 426-426.	0.8	3
141	Promoting patient engagement in bladder cancer (BC) care through education.. <i>Journal of Clinical Oncology</i> , 2018, 36, 176-176.	0.8	0
142	Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival. <i>Cancer Medicine</i> , 2017, 6, 186-194.	1.3	12
143	Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 312-322.	5.1	1,388
144	From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 509-512.e9.	0.9	1

#	ARTICLE	IF	CITATIONS
145	Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Are Things Now Getting Personal?. <i>European Urology</i> , 2017, 72, 555-556.	0.9	3
146	Moving beyond vascular endothelial growth factor-targeted therapy in renal cell cancer: latest evidence and therapeutic implications. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 287-298.	1.4	4
147	A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity. <i>Oncologist</i> , 2017, 22, 609-619.	1.9	253
148	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2017, 389, 67-76.	6.3	1,728
149	Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). <i>European Urology</i> , 2017, 71, 281-289.	0.9	56
150	Hospital Centralization Impacts High-Risk Lung and Bladder Cancer Surgical Patients. <i>Cancer Investigation</i> , 2017, 35, 652-661.	0.6	8
151	The Khorana Score in Predicting Venous Thromboembolism for Patients With Metastatic Urothelial Carcinoma and Variant Histology Treated With Chemotherapy. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 755-760.	0.7	17
152	Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 23-30.e2.	0.9	50
153	The role of GATA2 in lethal prostate cancer aggressiveness. <i>Nature Reviews Urology</i> , 2017, 14, 38-48.	1.9	71
154	Survival after Metastasectomy for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis. <i>Bladder Cancer</i> , 2017, 3, 121-132.	0.2	30
155	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. , 2017, 5, 68.		68
156	Web-Based Tool to Facilitate Shared Decision Making With Regard to Neoadjuvant Chemotherapy Use in Muscle-Invasive Bladder Cancer. <i>JCO Clinical Cancer Informatics</i> , 2017, 1, 1-12.	1.0	9
157	Telemedicine-Enabled Clinical Trial of Metformin in Patients With Prostate Cancer. <i>JCO Clinical Cancer Informatics</i> , 2017, 1, 1-10.	1.0	15
158	Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. <i>Journal of Clinical Investigation</i> , 2017, 127, 2081-2090.	3.9	155
159	A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS3114-TPS3114.	0.8	4
160	Therapy for chemopretreated metastatic urothelial cancer (mUC) with the antibody-drug conjugate (ADC) sacituzumab govitecan (IMMU-132).. <i>Journal of Clinical Oncology</i> , 2017, 35, 327-327.	0.8	5
161	Genomic differences between black and white patients implicate a distinct immune response to papillary renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 5196-5205.	0.8	22
162	The Relationship between Centralization of Care and Geographic Barriers to Cystectomy for Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 319-327.	0.2	21

#	ARTICLE	IF	CITATIONS
163	Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma1. <i>Bladder Cancer</i> , 2016, 2, 341-349.	0.2	7
164	Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank. <i>Bladder Cancer</i> , 2016, 2, 203-213.	0.2	3
165	Phase II Trial of Abiraterone Acetate Plus Prednisone in Black Men With Metastatic Prostate Cancer. <i>Oncologist</i> , 2016, 21, 1414-e9.	1.9	6
166	Development of target specific agents for bladder cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 361-368.	0.4	1
167	Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. <i>European Urology</i> , 2016, 70, 771-775.	0.9	69
168	Systemic therapy for metastatic bladder cancer in 2016 and beyond. <i>Future Oncology</i> , 2016, 12, 1179-1192.	1.1	5
169	All roads lead to <sc>PP</sc>2A: exploiting the therapeutic potential of this phosphatase. <i>FEBS Journal</i> , 2016, 283, 1004-1024.	2.2	244
170	Systemic adjuvant therapy for renal cell carcinoma: Any hope for future clinical trials?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 221-224.	0.8	2
171	Definitive Management of Primary Bladder Tumors in the Context of Metastatic Disease: Who, How, When, and Why?. <i>Journal of Clinical Oncology</i> , 2016, 34, 3495-3498.	0.8	11
172	Reply to E.M. Ruggeri et al and Y.-W. Hu. <i>Journal of Clinical Oncology</i> , 2016, 34, 3225-3226.	0.8	0
173	Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever. <i>European Urology</i> , 2016, 70, 707-708.	0.9	16
174	Emerging role of immunotherapy in urothelial carcinomaâ€”Immunobiology/biomarkers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 556-565.	0.8	23
175	Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 530.e15-530.e21.	0.8	38
176	Patterns of Bladder Preservation Therapyâ€”Utilization for Muscle-Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 405-413.	0.2	12
177	Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement. <i>Journal of Clinical Oncology</i> , 2016, 34, 2627-2635.	0.8	69
178	Adverse event reporting in oncology clinical trials - lost in translation?. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 893-896.	1.0	12
179	Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 825-832.	0.8	158
180	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2016, 387, 1909-1920.	6.3	3,077

#	ARTICLE	IF	CITATIONS
181	The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016, 69, 624-633.	0.9	25
182	Treatment of muscle invasive bladder cancer in the elderly: navigating the trade-offs of risk and benefit. <i>World Journal of Urology</i> , 2016, 34, 3-11.	1.2	21
183	Protein Profiling of Bladder Urothelial Cell Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0161922.	1.1	9
184	Combination effect of therapies targeting the PI3K- and AR-signaling pathways in prostate cancer. <i>Oncotarget</i> , 2016, 7, 76181-76196.	0.8	18
185	Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1259-1265.	1.1	5
186	Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells. <i>Journal of Visualized Experiments</i> , 2015, , 53182.	0.2	40
187	Reporting quality of abstracts in phase III clinical trials of systemic therapy in metastatic solid malignancies. <i>Trials</i> , 2015, 16, 341.	0.7	12
188	Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer. <i>Frontiers in Oncology</i> , 2015, 5, 129.	1.3	7
189	Clinical trial awareness: Changes over time and sociodemographic disparities. <i>Clinical Trials</i> , 2015, 12, 215-223.	0.7	58
190	Clinical Decision Making in Castration-resistant Prostate Cancer According to Baseline Prostate-specific Antigen: Are We Measuring Disease Burden or Disease Biology?. <i>European Urology</i> , 2015, 67, 231-232.	0.9	3
191	A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer. <i>Cancer Cell</i> , 2015, 27, 223-239.	7.7	128
192	Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy for Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 185-192.	0.9	2
193	How I treat bladder cancer in elderly patients. <i>Journal of Geriatric Oncology</i> , 2015, 6, 1-7.	0.5	26
194	Systemic therapy“differentiating the achievable from the achieved. <i>Nature Reviews Urology</i> , 2015, 12, 128-129.	1.9	3
195	The landscape of precision cancer medicine clinical trials in the United States. <i>Cancer Treatment Reviews</i> , 2015, 41, 385-390.	3.4	57
196	The Impact of Regionalization of Cystectomy on Racial Disparities in Bladder Cancer Care. <i>Journal of Urology</i> , 2015, 194, 36-41.	0.2	25
197	Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease. <i>Journal of Urology</i> , 2015, 194, 91-97.	0.2	62
198	Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 53-64.	0.8	11

#	ARTICLE	IF	CITATIONS
199	Neoadjuvant Chemotherapy in the Management of Muscle-Invasive Bladder Cancer. <i>Urologic Clinics of North America</i> , 2015, 42, 181-187.	0.8	7
200	First-line Treatment of Metastatic Disease. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 329-340.	0.9	10
201	Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. <i>Cancer</i> , 2015, 121, 2586-2593.	2.0	155
202	A robust blood gene expression-based prognostic model for castration-resistant prostate cancer. <i>BMC Medicine</i> , 2015, 13, 201.	2.3	14
203	A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer. <i>European Urology</i> , 2015, 67, 100-110.	0.9	122
204	Management of Metastatic Bladder Tumours. , 2015, , 627-646.		0
205	Current Approaches to the Management of Bladder Cancer in Older Patients. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e250-e256.	1.8	8
206	Adult Cancer Clinical Trials That Fail to Complete: An Epidemic?. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	106
207	Mind the gap: Efficacy versus effectiveness and pivotal prostate cancer clinical trial demographics. <i>Cancer</i> , 2014, 120, 2944-2945.	2.0	4
208	Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 17995-18000.	3.3	52
209	A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3581-3588.	3.2	90
210	Phase Ib/II Trial of Gemcitabine, Cisplatin, and Lenalidomide as First-Line Therapy in Patients With Metastatic Urothelial Carcinoma. <i>Oncologist</i> , 2014, 19, 915-916.	1.9	4
211	Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: A systematic review and meta-analysis of randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2014, 40, 636-647.	3.4	33
212	Is Metastatic Prostate Cancer Changing, and How Will We Know It? It's Time for Standard Nomenclature for Nonosseous Metastases in Clinical Trials of Patients with Metastatic Castration Resistant Prostate Cancer. <i>European Urology</i> , 2014, 66, 184-185.	0.9	2
213	Cisplatin-Ineligible and Chemotherapy-Ineligible Patients Should Be the Focus of New Drug Development in Patients With Advanced Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 71-73.	0.9	41
214	Toxicities Following Treatment with Bisphosphonates and Receptor Activator of Nuclear Factor- κ B Ligand Inhibitors in Patients with Advanced Prostate Cancer. <i>European Urology</i> , 2014, 65, 278-286.	0.9	41
215	Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 48.e1-48.e8.	0.8	10
216	Metastatic Renal Cancer: Better Never Than Late. <i>European Urology</i> , 2014, 65, 1093-1094.	0.9	4

#	ARTICLE	IF	CITATIONS
217	Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65years of age with stage III non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2014, 112, 272-278.	0.3	26
218	Adverse Event Reporting in Cancer Clinical Trial Publications. <i>Journal of Clinical Oncology</i> , 2014, 32, 83-89.	0.8	122
219	Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 465-471.	1.1	14
220	Use of Crowdsourcing for Cancer Clinical Trial Development. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	37
221	Targeting Vascular Endothelial Growth Factor Receptor Signaling in Renal Cancer: The Sooner the Better?. <i>European Urology</i> , 2014, 66, 881-883.	0.9	1
222	Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 30.e15-30.e21.	0.8	14
223	Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 130-137.	0.9	27
224	Patient Eligibility and Trial Design for the Salvage Therapy of Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 395-398.	0.9	12
225	T2 Muscle-Invasive Bladder Cancer. <i>Seminars in Oncology</i> , 2014, 41, e11-e18.	0.8	0
226	Biomarkers for bladder cancer management: present and future. <i>American Journal of Clinical and Experimental Urology</i> , 2014, 2, 1-14.	0.4	36
227	Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. <i>World Journal of Urology</i> , 2013, 31, 1535-1539.	1.2	61
228	Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States. <i>World Journal of Urology</i> , 2013, 31, 1211-1217.	1.2	14
229	A prognostic model for metastatic renal-cell carcinoma. <i>Lancet Oncology</i> , The, 2013, 14, 102-103.	5.1	11
230	Risk of hematologic toxicities in patients with solid tumors treated with everolimus: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 30-41.	2.0	10
231	Risk of hematologic toxicities in cancer patients treated with sunitinib: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2013, 39, 818-830.	3.4	31
232	Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2013, 16, 266-270.	2.0	2
233	Pooled Analysis of Phase II Trials Evaluating Weekly or Conventional Cisplatin as First-Line Therapy for Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 316-320.	0.9	5
234	Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 80-89.	2.0	63

#	ARTICLE	IF	CITATIONS
235	Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials. <i>European Urology</i> , 2013, 63, 717-723.	0.9	104
236	Tumour angiogenesis: an elusive target in castration-resistant prostate cancer. <i>Lancet Oncology</i> , The, 2013, 14, 681-682.	5.1	6
237	Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 175-181.	0.9	78
238	Critical analysis of contemporary clinical research in muscle-invasive and metastatic urothelial cancer. <i>Cancer</i> , 2013, 119, 1994-1998.	2.0	12
239	Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy. <i>Cancer</i> , 2013, 119, 3020-3026.	2.0	9
240	Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. <i>Cancer</i> , 2013, 119, 3012-3019.	2.0	82
241	Advances in the management of muscle-invasive bladder cancer through risk prediction, risk communication, and novel treatment approaches. <i>Clinical Advances in Hematology and Oncology</i> , 2013, 11, 86-92.	0.3	6
242	Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 4416-4426.	0.8	197
243	Arterial Thromboembolism in Cancer Patients Treated With Cisplatin: A Systematic Review and Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1837-1840.	3.0	34
244	Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors. <i>Annals of Oncology</i> , 2012, 23, 1037-1044.	0.6	11
245	Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. <i>Annals of Oncology</i> , 2012, 23, 406-410.	0.6	214
246	Novel molecular targets for the therapy of urothelial carcinoma. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 499-513.	1.5	1
247	Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: A meta-analysis. <i>Cancer Treatment Reviews</i> , 2012, 38, 919-925.	3.4	53
248	Is Adjunctive Systemic Chemotherapy After Cystectomy for T2N+ Disease of Therapeutic Benefit?. <i>Journal of Urology</i> , 2012, 188, 358-360.	0.2	3
249	Emerging personalized approaches for the management of advanced urothelial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1537-1543.	1.1	6
250	Prevalence and characteristics of patients with metastatic cancer who receive no anticancer therapy. <i>Cancer</i> , 2012, 118, 5947-5954.	2.0	39
251	Impact of the CKD-EPI Equation for Estimating Renal Function on Eligibility for Cisplatin-based Chemotherapy in Patients With Urothelial Cancer. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 15-20.	0.9	38
252	Clinical development of novel therapeutics for castration-resistant prostate cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2012, 62, 299-308.	157.7	40

#	ARTICLE	IF	CITATIONS
253	Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. <i>Investigational New Drugs</i> , 2012, 30, 695-701.	1.2	50
254	New Developments in Urothelial Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 304-308.	1.8	1
255	A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. <i>Lancet Oncology</i> , The, 2011, 12, 211-214.	5.1	261
256	Retrospective Analysis of Satraplatin in Patients with Metastatic Urothelial Cancer Refractory to Standard Platinum-Based Chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2011, 9, 27-30.	0.9	5
257	Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2011, 29, 287-293.	0.8	155
258	Reply to O. Dizdar et al. <i>Journal of Clinical Oncology</i> , 2011, 29, 3945-3946.	0.8	0
259	Treatment of Patients With Metastatic Urothelial Cancer "Unfit" for Cisplatin-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2011, 29, 2432-2438.	0.8	514
260	Bladder Cancer: Current Management and Opportunities for a Personalized Approach. <i>Mount Sinai Journal of Medicine</i> , 2010, 77, 587-596.	1.9	8
261	Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics. <i>Investigational New Drugs</i> , 2010, 28, 194-198.	1.2	11
262	Cabazitaxel. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 677-678.	21.5	152
263	First-Line Systemic Therapy Trials for Advanced Transitional-Cell Carcinoma of the Urothelium: Should We Stop Separating Cisplatin-Eligible and -Ineligible Patients?. <i>Journal of Clinical Oncology</i> , 2010, 28, e441-e442.	0.8	19
264	Cytotoxic chemotherapy for castration resistant prostate cancer: 2010 and beyond. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2010, 7, 17-22.	0.5	2
265	Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. <i>Lancet Oncology</i> , The, 2010, 11, 861-870.	5.1	123
266	Phase I Trial of the Prostate-Specific Membrane Antigen-Directed Immunoconjugate MLN2704 in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 2147-2154.	0.8	135
267	Prospective Trial of Ifosfamide, Paclitaxel, and Cisplatin in Patients with Advanced Non-transitional Cell Carcinoma of the Urothelial Tract. <i>Urology</i> , 2007, 69, 255-259.	0.5	79
268	Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function. <i>Cancer</i> , 2007, 109, 549-555.	2.0	52
269	Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. <i>Investigational New Drugs</i> , 2007, 25, 265-270.	1.2	124
270	Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. <i>Cancer</i> , 2006, 107, 506-513.	2.0	360

#	ARTICLE	IF	CITATIONS
271	The Integration of Chemotherapy and Surgery for Bladder Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2005, 3, 45-51.	2.3	9
272	The Role of Taxanes in the Management of Bladder Cancer. Oncologist, 2005, 10, 792-798.	1.9	30